Background
==========

The Runt domain (Runx) is a highly conserved, 128 amino acid sequence that defines a small family of heterodimeric transcription factors that are key regulators of animal development (reviewed in \[[@B1]\]). Most developmental studies of Runx gene function have been carried out in *Drosophila*and in mice, each of which has multiple Runx genes. The genome of *Drosophila melanogaster*contains four Runx genes, including the well-studied genes *runt*and *lozenge*, as well as two genes (genomic loci CG1379 and CG15455) that have not been well-characterized \[[@B2]\]. *Runt*is a primary pair rule gene involved in segmentation, sex determination and neurogenesis, whereas *lozenge*is a key regulator of patterning in the eye (reviewed in \[[@B3]\]). Mammalian genomes contain three Runx genes, each of which is essential for development of a major organ system: *Runx1*is required for hematopoiesis, *Runx2*is required for osteogenesis, and *Runx3*is required both for proprioceptive neurogenesis in the dorsal root ganglia and for normal stomach development (reviewed in \[[@B1]\]). All three mammalian Runx genes are associated with cancer, and *RUNX1*is a frequently mutated gene in acute leukemia \[[@B4]\]. The multiplicity of Runx genes in insects and vertebrates reflects independent duplication events within the arthropod and chordate lineages, and the primitive condition within bilaterians appears to be possession of a single Runx gene \[[@B2]\].

The sea urchin *Strongylocentrotus purpuratus*has a single Runx gene, *SpRunt*\[[@B5],[@B6]\]. SpRunt was discovered biochemically through its specific regulatory interaction with the *CyIIIa*actin gene \[[@B7],[@B8]\]. The Runx target sequence in the *CyIIIa cis*-regulatory domain is required for transcriptional activation, particularly after gastrulation when high levels of *CyIIIa*expression accompany terminal differentiation of the aboral ectoderm \[[@B8]\]. However, in the gastrula-stage embryo the highest levels of SpRunt mRNA are found not in aboral ectoderm, but rather in oral ectoderm and endomesoderm, a spatial pattern that is essentially isomorphic with that of continued growth and cell proliferation \[[@B5]\]. SpRunt mRNA is absent in unfertilized eggs, and accumulates zygotically to an initial steady-state level of \~700 molecules per embryo by morula stage, after which it accumulates further to a 10-fold higher level between mid-blastula and early gastrula stage \[[@B8]\]. In adults, *SpRunt*expression has been shown to be an early response of the immune system to bacterial challenge \[[@B9]\].

The current study was undertaken to further define the role of *SpRunt*in sea urchin embryogenesis.

Results and discussion
======================

Morpholino antisense targeting of *SpRunt*
------------------------------------------

Morpholino antisense oligonucleotides can be used to sequence-specifically block translation \[[@B10]\] or pre-mRNA splicing \[[@B11]\]. We employed both strategies to study *SpRunt*function, using morpholinos that target sequences within exon 1 (m1, m2, and m3) and the first two exon-intron junctions (m4 and m5; Figure [1A](#F1){ref-type="fig"}). To test the efficacy of the translation-blocking morpholinos, zygotes were injected with m1, m2, or m3 or a non-specific control morpholino (mC), together with synthetic SpRunt mRNA (\>100-fold excess over endogenous levels), and the resulting embryos analyzed by immunoblot using an antibody generated against the N-terminal peptide of SpRunt. Zygotic translation of full-length SpRunt protein from exogenous mRNA is completely blocked by m1 and partially blocked by m2, but not at all by m3, which targets a potential secondary translational start site (Figure [1B](#F1){ref-type="fig"}). To test the efficacy of the splice-blocking morpholinos, we performed RT-PCR on total RNA isolated from embryos injected with m4, m5, or mC. While both m4 and m5 interfere with production of full-length SpRunt mRNA, m4 is somewhat more effective than m5 (Figure [1C](#F1){ref-type="fig"}). In addition, m5 induces production of a transcript that retains intron 2 (which encodes a truncated protein with a complete Runt domain, and hence a potentially functional protein), and also skipping of exon 2, producing an aberrant transcript that fuses exon 3 directly to exon 1 (data not shown).

Morpholinos 1 and 4 produce a cleavage stage artifact by mis-targeting to histone mRNA
--------------------------------------------------------------------------------------

Embryos injected with anti-SpRunt morpholinos develop two distinctive phenotypes: an early blastula stage arrest (Figure [2](#F2){ref-type="fig"}) and a later gastrula-stage arrest (Figure [3](#F3){ref-type="fig"}; see below). We initially interpreted this as reflecting complete versus partial loss of SpRunt function, since the more severe early phenotype is obtained with the two morpholinos that are most effective at knocking down SpRunt (that is, m1 and m4; see Figure [1](#F1){ref-type="fig"}). By late cleavage-stage, all of the nuclei in m1- or m4-injected embryos are abnormal (Figure [2B,2C](#F2){ref-type="fig"}; compare to control in Figure [2A](#F2){ref-type="fig"}), with a \'cut\'-like phenotype indicative of a failure to segregate mitotic chromosomes (Figure [2C](#F2){ref-type="fig"}, arrow). Counts of nuclei and time-lapse imaging show that these embryos undergo a global mitotic catastrophe during cleavage cycle 7 or 8 (data not shown). For both m1 and m4, this phenotype is obtained in \>95% of embryos injected with morpholino doses of \~1--2 μM, comparable to effective dosage in other studies \[[@B10],[@B12]\].

At the time of arrest, m1-injected embryos contain substantially fewer histones per unit DNA than do control embryos (Figure [2D](#F2){ref-type="fig"}), a defect that is known to cause mitotic catastrophe in other systems \[[@B13]-[@B15]\]. To determine if the histone deficit is caused by a failure of histone synthesis, we analyzed metabolically-labeled protein from morpholino-injected embryos. Surprisingly, m1-injected embryos are specifically deficient in synthesis of histone H3 (Figure [2E](#F2){ref-type="fig"}, lane 2), whereas m4-injected embryos are deficient in synthesis of histone H4 (Figure [2E](#F2){ref-type="fig"}, lane 3). This led us to suspect that the cell division phenotype of m1- and m4-injected embryos might be caused by antisense mis-targeting to mRNA encoding H3 and H4, respectively. In fact, significant similarity (18/25) is found between the m1 target sequence and two non-contiguous blocks of sequence near the start codon of H3 (Figure [2F](#F2){ref-type="fig"}), and a similar situation (20/25) obtains for the target sequence of m4 and H4 (Figure [2G](#F2){ref-type="fig"}). The gaps and mismatches would suggest that mis-targeting of the morpholinos to the histone mRNA should not occur; however, *S. purpuratus*embryos develop at 15°C, which would reduce the stringency for hybridization. In addition, the relatively high concentration of histone mRNA would tend to drive the imperfect hybridization with the morpholinos.

When m1 is co-injected with synthetic H3 mRNA (0.1 mg/ml), translation of the exogenous histone mRNA is indeed blocked (Figure [2H](#F2){ref-type="fig"}; compare lanes 2 and 3). However, co-injection of sufficiently high levels of H3 mRNA (≥1 mg/ml) rescues m1-injected embryos from mitotic catastrophe (Figure [2I](#F2){ref-type="fig"}), whereas similar levels of H3 mRNA do not rescue m4-injected embryos (not shown). Co-injection of SpRunt mRNA lacking the m1 target sequence does not rescue either m1- or m4- injected embryos (not shown). We conclude that m1-injected embryos undergo mitotic catastrophe because of antisense mis-targeting to histone H3 mRNA, whereas the mitotic catastrophe in m4-injected embryos is probably caused by mis-targeting to histone H4 mRNA. These results show that production of similar defects by two different morpholinos that target the same gene does not prove that the defects are caused by knockdown of the intended target.

Morpholinos 2 and 5 cause gastrula stage developmental defects
--------------------------------------------------------------

Embryos injected with m2 or m5 appear relatively normal through mesenchyme blastula stage (not shown), but thereafter develop numerous obvious defects. By late gastrula stage, the embryos are smaller than controls, and display differentiation and/or patterning defects in all of the major tissue territories: the ectoderm is radialized, the primary mesenchyme cells fail to undergo skeletogenesis, and the gut rudiment is short, disorganized, and typically evaginates as an exogastrula (Figure [3C,3D](#F3){ref-type="fig"}; compare to controls in Figure [3A,3B](#F3){ref-type="fig"}). Pigment cells do eventually develop however, indicating that some differentiation occurs.

Although m2- and m5-injected embryos develop indistinguishable defects, the coincidental mis-targeting artifact obtained with m1 and m4 compelled us to use a rescue approach to prove that these defects are caused by loss of SpRunt function. Since m5 is a splice-blocking morpholino that targets the second exon-intron junction, it would not be expected to block SpRunt translation, and we reasoned that it should therefore be possible to suppress the defects observed in m5-injected embryos by co-injection of wild-type SpRunt mRNA. This is indeed the case (Figure [3E,3F](#F3){ref-type="fig"}): in three separate experiments with injection solutions containing 1 mg/ml SpRunt mRNA (\~6 kb), 30--50% of embryos had the rescue phenotype depicted in Figure [3](#F3){ref-type="fig"}, while the remainder of the embryos were somewhat more normal looking than those injected with morpholino alone (for example, with longer exogastrulated guts). The incomplete penetrance of the rescue is probably due to turnover of the injected mRNA by gastrula stage. In contrast, only 10--15% of embryos injected with m5 alone display a normal phenotype (probably as a result of under-injection).

The small size of SpRunt-depleted embryos suggests that they might be defective in growth and/or cell proliferation. Consistent with such a possibility, embryos injected with m5 were found to contain about half the DNA content of control embryos by 48 hours post-fertilization (late gastrula stage; data not shown). We used cytometry to further examine the DNA content in these embryos. Compared to controls of the same age (Figure [3G](#F3){ref-type="fig"}), m5-injected embryos at 48 hours post-fertilization display an abnormally high proportion of cells in G2/M phase (Figure [3H](#F3){ref-type="fig"}), a defect that is rescued by co-injection of SpRunt mRNA (Figure [3I](#F3){ref-type="fig"}), indicating that SpRunt is required for the normal developmental program of cell division. This is consistent with the expression pattern of SpRunt, which is isomorphic with the pattern of cell proliferation in the embryo \[[@B5]\].

Quantitative RT-PCR (Q-PCR) was used to examine the effect of SpRunt knockdown on gene expression (Table [1](#T1){ref-type="table"}). The data in Table [1](#T1){ref-type="table"} indicate that SpRunt is required for the expression of differentiation genes in each of the four major territories of the embryo (that is, oral ectoderm, aboral ectoderm, vegetal plate endomesoderm, and skeletogenic mesoderm). One of the genes whose activity is most dramatically affected by depletion of SpRunt is *SpDri*, which encodes a transcription factor that is important for gastrula stage differentiation of oral ectoderm \[[@B16]\]. Expression of *SpGsc*, another transcription factor important for oral ectoderm differentiation \[[@B17]\], is also diminished (Table [1](#T1){ref-type="table"}). This may be a secondary effect, as *SpGsc*is likely to be a target of *SpDri*\[[@B16]\]. *SpRunt*is also required for normal expression levels of terminal differentiation markers such as *CyIIIa*in aboral ectoderm, *Endo16*in endoderm, and *SM50*in skeletogenic mesoderm (Table [1](#T1){ref-type="table"}). It is possible that the skeletogenic defects are a non-autonomous consequence of the failure to differentiate ectoderm \[[@B18]\], although the fact that SpRunt is expressed at relatively high levels in skeletogenic mesenchyme \[[@B5]\] is consistent with an autonomous requirement. Moreover, a sequence that contains the Runx binding consensus (TG^T^/~C~GGT^T^/~C~) is found upstream of the promoter of the *SM50*gene (A.J.R., unpublished observation).

In support of a role in cell proliferation, SpRunt is required for normal levels of cyclins B and D, which are expressed in a proliferation-specific pattern similar to that displayed by *SpRunt*\[[@B19],[@B20]\]. In addition, SpRunt positively regulates the expression of protein kinase C (PKC; Table [1](#T1){ref-type="table"}). Interestingly, human *PKCβ*has been shown to be a direct target of *RUNX1*\[[@B21]\]. Given the wide variety of developmental signaling processes that utilize protein kinase C, it is possible that a significant number of the later defects in SpRunt morphant embryos develop as a consequence of loss of *PKC*expression.

Although loss of SpRunt function appears to have global effects on development, the expression of a number of genes is not affected, which argues against a non-specific effect on gene expression caused by a general arrest of development. Moreover, loss of SpRunt function has stage-specific effects on the expression of each of genes listed in Table [1](#T1){ref-type="table"}, in some cases early, and in others late. The expression of some genes (for example, *Spec2a*, *ARS*, *Otxβ3*, and *Endo16*) is affected more strongly at mesenchyme blastula stage than at late gastrula stage, and the opposite is true for several other genes (for example, *SpDri*, *cyclinD*, and *Otxα*). A few genes are affected at both stages assayed (for example, *CyIIIa*, *PKC*, and *SM50*). In most cases, knockdown of SpRunt causes a diminishment in gene expression levels, consistent with its previously identified function as an activator of *CyIIIa*\[[@B8]\]. However, in the cases of *Otxα*and *cyclinA*there is an elevation in expression at 48 hours. Normally *Otxα*levels are greatly diminished at this stage of development \[[@B22]\], and it is possible that this involves SpRunt mediated repression.

The stage-specific effects of SpRunt knockdown on gene expression are consistent with the proposition that SpRunt functions within the context of one or more *cis*-regulatory modules in each target gene, thereby regulating a temporal and/or spatial sub-element of the target gene\'s overall expression pattern, as is the case with *CyIIIa*\[[@B8],[@B23]\]. While further work using chromatin immunoprecipitation and *cis*-regulatory analysis will be necessary to determine which of the affected genes in Table [1](#T1){ref-type="table"} are direct targets of SpRunt, these data demonstrate that *SpRunt*is required globally for both cell proliferation and differentiation, and is likely to be a key node in the gene regulatory network that coordinates these processes during embryogenesis. Understanding of how this is accomplished will require a comprehensive analysis of the relevant gene regulatory network, and this is in progress.

Conclusions
===========

In both *Drosophila*and in mice, Runx proteins are expressed in localized domains and are important for the development of specific structures, and are thus often referred to as cell lineage or tissue-specific transcription factors. Unlike sea urchins, both insects and vertebrates have multiple Runx genes \[[@B2]\], which may reflect the greater regulatory network complexity in these organisms (that is, the Runx paralogs may reflect a requirement for expression variants as opposed to functionally distinct proteins). Our results suggest that *SpRunt*is required for normal development in all of the embryonic tissues. This would not have been predicted based on its spatial pattern of expression, which in the post-gastrula stage embryo is confined to actively dividing cells \[[@B5]\]. Nonetheless, SpRunt clearly functions autonomously to promote the gastrula stage differentiation of aboral ectoderm \[[@B8]\], wherein its mRNA (but not protein; J.A.C., unpublished) is virtually undetectable \[[@B5]\]. Rather than specifying cell fate *per se*, SpRunt is probably required as a \'promoter organizer\' \[[@B24]\] for the normal functioning of a variety of different territory-specific transcription factors. It is possible that Runx genes are generally required for coordinating cell proliferation and differentiation during animal development, a requirement that would be masked by the idiosyncrasies of their mRNA expression patterns as well as by functional redundancies between paralogs in model systems that contain multiple Runx genes.

Methods
=======

Animals, embryo culture, and microinjection
-------------------------------------------

*Strongylocentrotus purpuratus*were obtained from Marinus, Inc. (Long Beach, CA, USA), Charles Hallohan (Santa Barbara, CA, USA), or Pat Leahy (Corona del Mar, CA, USA). Gamete collection, fertilization, embryo culture, and microinjection were carried out as previously described \[[@B8]\]. For metabolic labeling, embryos were incubated in 14 μCi ^35^S-Met/Cys (\>1000 Ci/mmole; APBiotech, Piscataway, NJ, USA) in a total of 1 ml artificial seawater (ASW) at 15°C.

Morpholino antisense oligonucleotides
-------------------------------------

The following morpholinos were purchased from GeneTools, LLC (Philomath, OR, USA): ACGCGAGTGGTTTGTATCGAGATGA (m1); GATGAAAGGGCGGGAAAAAATGATT (m2); TAACTGTTATGTAGGTTGTTCCTCC (m3); ATTTTCCAACTTACCTCGACCCGAT (m4); and GGTATGACTTACGTCTGGGTTCTC (m5).

Target site selection and design of each morpholino was performed by GeneTools. The standard control morpholino (mC) from GeneTools was used as a non-specific control. Prior to injection, morpholinos were diluted to 150--400 μM in 120 mM KCl.

Synthetic mRNA
--------------

For immunoblot analyses of morpholino-injected embryos, DNA sequence encoding SpRunt \[[@B8]\] was amplified by PCR using the primers: GGGGTACCCCGCCACTTGTCCACATGTATACT (forward) and GCTCTAGAATATGGCCGCCAGACGTCCTCTT (reverse). The amplified fragment was digested with Kpn1 and Xba1 and cloned into pBluescript (Stratagene, La Jolla, CA, USA) between the T7 promoter and the pre-inserted Xba1/Sac1 fragment of pXFRM \[[@B25]\] containing the *Xenopus*β-globin gene 3\' UTR and polyadenylation site. The resulting plasmid, pRFLβ, was verified by sequence analysis and linearized with Sac1 for mRNA synthesis. For rescue experiments, the 3\' UTR of SpRunt (including the poly A signal and tail) was amplified from cDNA using the primers CAGATCGCTACCTACAACCGTGCAA (forward) and TTTTTTTTTTCAAAGTGAACAGAGTGTTTTA (reverse) and cloned into pGEM-T Easy (Promega, Madison, WI, USA). This plasmid was digested with AatII to release the insert, which was then cloned into the AatII sites of the original SpRunt clone \[[@B8]\] to generate a plasmid containing the full-length sequence of the SpRunt mRNA. Following verification by sequencing, this plasmid was used as a PCR template to amplify full-length SpRunt, using the T7 primer and the reverse primer representing the SpRunt poly A tail (see above), and the resulting amplicon was then used for mRNA synthesis. Capped synthetic mRNA was made with the T7 mMessage Machine from Ambion (Austin, TX, USA).

Microscopy and cytometry
------------------------

Staged embryos were fixed in 4% formaldehyde in filtered ASW for 20 min to 6 hrs on ice, then washed 3× with PBS and into PBS plus 0.2% Tween-20 (PBST). To detect nuclei and cell boundaries, embryos were stained for 5--10 mins with rhodamine phalloidin (Molecular Probes, Eugene, OR, USA) at 1:40 and DAPI (Molecular Probes) at 300 nM in PBST, and washed 3× in PBS. Digital images were collected using either a Zeiss Axioplan or a Leica TCS SP2 confocal microscope.

For DNA analysis, embryos grown at 15°C were collected by centrifugation, washed once 1 M Glycine, 2 mM EDTA, pH 8, and then resuspended in calcium-free seawater. The embryos were dissociated into single cells by mild trituration, and stained with propidium iodide (PI) using the PI Stain kit from Sigma (St. Louis, MO, USA). PI fluorescent signal (580/30 nm) was measured using a Cyan flow cytometer (Dako-Cytomation, Fort Collins, CO, USA). Approximately 10,000 events were collected per sample. DNA ploidy analysis was performed using ModFit LT software (Verity Software House, Topsham, ME, USA).

Isolation of nuclei and DNA fluorometry
---------------------------------------

Embryos were lysed by incubation for 15 minutes on ice in \~5 volumes of hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl~2~, 10 mM KCl, 1 mM DTT) supplemented with a general protease inhibitor cocktail (Sigma), followed by addition of Igepal CA-630 (Sigma) to a final concentration of 0.6% and vortexing for 10 seconds. Nuclei were then isolated by centrifugation for 30 seconds at 10,000 g. The nuclear pellet was resuspended in \~5 volumes Buffer D (25 mM Hepes pH 7.5, 5 mM MgCl~2~, 0.1 mM EDTA, 1 mM DTT, 1 mM Spermidine, 0.1 mM PMSF), and the DNA content was quantitated by fluorometry using Hoechst 33258 (Sigma) and the Hoefer DyNA Quant 200 system (APBiotech).

SDS polyacrylamide electrophoresis (PAGE) and immunoblots
---------------------------------------------------------

Protein samples (representing equivalent total protein, as determined by the method of Bradford \[[@B26]\]), whole nuclei (representing equivalent total DNA, as determined by fluorometry), or whole ^35^S-labeled embryos (equivalent numbers, as determined by manual counts) were mixed with an equal volume of 2× SDS sample buffer, heated to 95°C for 5 min, and run on a 10% NuPAGE Bis-Tris gel (Invitrogen, Carlsbad, CA, USA). Gels were dried and imaged, stained with SYPRO Ruby (Bio-Rad, Hercules, CA, USA) and imaged directly, or transferred to a nitrocellulose membrane. Radioactive and fluorescent gels were imaged on a Typhoon 8600 phosphorimager (APBiotech). For immunoblots, the membrane was incubated for 1 hr in TBS-T (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) with 5% nonfat milk (TBS-TM), and then incubated in TBS-TM containing an appropriate dilution of primary antibody overnight at 4°C. Following four washes for 5 min each with TBS-T, the membrane was incubated for 1 hr at room temperature in TBS-TM containing 2 ng/ml of goat anti-rabbit IgG HRP conjugate (Biosource International, Camarillo, CA, USA). The membrane was then washed 5× for 5 min each in TBS-T, incubated for 4 min in Super Signal West Femto substrate (Pierce Biotech, Rockford, IL), and exposed to Kodak X-OMAT film.

The SpRunt antibody was raised against the N-terminal peptide of SpRunt, and affinity purified on a column bearing the peptide antigen.

Reverse transcription and quantitative polymerase chain reaction
----------------------------------------------------------------

Total RNA was isolated from morpholino injected embryos using the RNeasy mini kit (Qiagen, Valencia, CA, USA), and quantified with the RiboGreen Quantification Kit (Molecular Probes). Quantitative, real-time, one-step RT-PCR was performed using the Qiagen QuantiTect SYBR Green RT-PCR kit and the fluorescence measured in a BioRad iCycler. Starting with 50 ng of total RNA and 0.4 μM of each primer the reaction was set up and run following the Qiagen recommended protocol. For quantitative real-time PCR (Q-PCR) measurements, determination of the ratio of target in the control versus the sample was calculated as 1.9^ΔCt^, where ΔC~t~represents the ubiquitin-normalized difference in the number of cycles needed to obtain the threshold fluorescence intensity (C~t~) in control morpholino injected versus SpRunt-morpholino injected samples for each primer pair \[[@B16]\]. Initial PCR reactions were also performed using Qiagen OneStep RT-PCR kit and visualized by ethidium bromide in agarose gels to ensure that there was only a single product formed under the conditions used for each primer pair. Primer sequences used for the RT-PCR and Q-PCR reactions are listed in the Supplemental Table \[see [Additional file 1](#S1){ref-type="supplementary-material"}\].
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![Morpholino antisense targeting of SpRunt. **(A)**Schematic of *SpRunt*, showing the relative locations of sequences targeted by each of the five morpholinos used in this study. Exons 1--3 are depicted as boxes, with coding regions shaded. The Runt domain is black. Horizontal arrows indicate the positions of primers used for the RT-PCR shown in (C). **(B)**Immunoblots of protein translated *in vivo*from injected SpRunt mRNA co-injected with control morpholino (mC), m1, m2, or m3. As a loading control, the same blots were probed with an antibody to the sea urchin stem-loop binding protein (SLBP). **(C)**RT-PCR of SpRunt from total RNA extracted from early blastula stage embryos injected with mC, m4 or m5 (two separate experiments). RT-PCR of ubiquitin was used to control for RNA levels.](1741-7007-2-6-1){#F1}

![Embryos injected with anti-SpRunt m1 and m4 undergo a mitotic catastrophe caused by antisense mis-targeting to histone mRNA. **(A-C)**Confocal images of fixed 15 hr embryos stained with DAPI (blue) and rhodamine phalloidin (red). (A) Control (mC)-injected embryo, (B) m1-injected embryo, and (C) m4-injected embryo. The arrow indicates a pair of \'cut\' cells. Bar = 10 μm. **(D)**SDS PAGE of whole nuclei containing equivalent amounts of DNA (0.5 μg) from 14-hour control (mC) and m1-injected samples, stained with SYPRO Ruby protein stain. The positions of core histones, obtained from the mobility of calf thymus histone standards run on the same gel, are shown on the left of the gel, while the positions of molecular weight standards are indicated on the right. **(E)**Total protein from 600 mC-, m1-, or m4-injected embryos labeled metabolically with ^35^S-Met/Cys from 4 to 8 hours post-fertilization (hpf). Histones are easily identified by their characteristic size and stoichiometry, and by the fact that at this stage they represent \~5--10% of the total protein synthesized in the embryo \[27\]. The positions of histones H3 and H4 are indicated. **(F, G)**Sequence alignment between (F) the target sequence for m1 and α-histone H3 mRNA, and (G) the target sequence for m4 and α-histone H4 mRNA. Sequence identities are highlighted in black. The start codons are underlined in each sequence. **(H)***In vivo*translation of synthetic histone H3 mRNA co-injected with m1. The injected zygotes were labeled metabolically with ^35^S-Met/Cys for 2 hours, during the first cleavage cycle. **(I)**15-hr blastula stage embryo, stained as in A-C, showing rescue of m1-induced cell division defects by co-injection of 1 μg/μl H3 mRNA; bar = 10 μm.](1741-7007-2-6-2){#F2}

![Phenotype of late gastrula stage embryos injected with anti-SpRunt m2 and m5. DIC images (A-F) and cytometric analysis (G-I) of 48 hour embryos. **(A)**Control morpholino (mC)-injected embryo, cross section, with the oral side to the left and the gut indicated by an arrowhead. Bar = 20 μm. **(B)**mC-injected embryo, oral view, with the skeletal spicules indicated by an arrow (sp). **(C)**m2-injected embryo. **(D)**m5-injected embryo. **(E-F)**Embryos co-injected with m5 and SpRunt FL mRNA, showing the rescued development of gut (E) and spicule rudiments (F). **(G)**DNA histogram of mC-injected embryos. **(H)**DNA histogram of m5-injected embryos; note the accumulation of cells in G2/M. **(I)**DNA histogram of embryos co-injected with m5 and SpRunt mRNA. Note the reduced accumulation of cells in G2/M compared to the embryos injected with m5 alone.](1741-7007-2-6-3){#F3}

###### 

Q-PCR analysis of gene expression in SpRunt morphant embryos

  **Function**           **Gene**             **24 hpf**                **48 hpf**
  ---------------------- -------------------- ------------------------- --------------------------------
  Transcription factor   *Runt*               NS                        NS/NS/NS
                         *Myb*                **-3.9**/NS/NS            NS/NS/NS
                         *Dri*(OE)            **-2.3**/NS/**-2.5**      **-12/-8.9/-6.9/-2.6/-7.6/-3**
                         *Hnf6*(OE)           NS/NS                     **-2.5**/NS/**-3.1/-2.5**
                         *Gsc*(OE)            **-2.4**/NS/NS            **-3.7/-2.3/-2.4/-4.7/-5.1**
                         *Otxα*(VPEM early)   NS/NS                     **+5.2/+4.8/+10.5/+10.2**
                         O*txβ1*(OE)          **-2.4/-1.9**             NS/NS/NS/NS
                         *Otxβ3*(VPEM+OE)     **-2.4/-2.4**             NS**/+3.5**/NS/NS/NS
  Cell cycle control     *CyclinD*            NS/NS/NS                  **-2.9/-2.7/-4.8/-2**
                         *CyclinE*            NS/-2                     NS/**-2.6**/NS/NS
                         *CyclinA*            NS                        NS/**+3.6/+5.8/+3/+2**
                         *CyclinB*            **-2.4/-2.5/-2.2**        **-3.7**/NS/NS
                         *Wee1*               NS/NS                     **-2.5**/NS/NS/NS
                         *Cdk4*               NS                        NS/NS/NS
  Signal transduction    *PKC*                NS/**-2/-3**              **-8.8/-8/-7.7/-4.9/-5.4**
  AE differentiation     *CyIIIa*\*           **-2.7/-1.9/-2**          **-2.4/-2.3/-3.8/-3**
                         *Spec2a*             **-2.1/-2.3/-2.3/-3.4**   NS/NS/NS/**-3.9**
                         *ARS*                **-3.9/-2.4**             NS/NS/NS/NS
  VPEM differentiation   *Endo16*             **-6.8/-3.4**             **-1.8/-2.4**/NS/NS/NS
  SM differentiation     *SM50*               **-2.4/-2.3/-2.6**        **-9.6/-3/-4.3**/NS/NS/NS
                         *SM30*               NS/NS                     **-4.1**/NS/NS/NS
                         *Msp130*             **-5.7**/NS               NS/**-2.7**/NS/NS

\**CyIIIa*was identified previously by *cis*-regulatory analysis as a direct target of SpRunt \[8\]. Each number indicates fold-difference in transcript levels in SpRunt-m5-injected embryos compared to controls (triplicate average for a single experiment), measured as described in Methods. Based on the results obtained with *CyIIIa*, fold-differences of less than a factor of 2 (\~1 cycle) were scored as not significant (NS). hpf, hours post-fertilization; AE, aboral ectoderm; OE, oral ectoderm; VPEM, vegetal plate endomesoderm (gut and secondary mesoderm); SM, skeletogenic mesoderm.
